Logo image
Management of dyslipidaemia in patients with comorbidities-facing the challenge: type 1 diabetes mellitus
Journal article   Peer reviewed

Management of dyslipidaemia in patients with comorbidities-facing the challenge: type 1 diabetes mellitus

Susanne Kaser, Dobromir Dobrev, Bianca Rocca, Juan Carlos Kaski, Stefan Agewall and Heinz Drexel
European heart journal. Cardiovascular pharmacotherapy, v 11(4), pp 380-386
01 Jul 2025
PMID: 40396997

Abstract

Biomarkers - blood Cardiovascular Diseases - diagnosis Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - diagnosis Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 1 - epidemiology Dyslipidemias - blood Dyslipidemias - diagnosis Dyslipidemias - drug therapy Dyslipidemias - epidemiology Humans Hypolipidemic Agents - adverse effects Hypolipidemic Agents - therapeutic use Lipids - blood Risk Assessment Risk Factors Treatment Outcome Comorbidity
Type 1 diabetes is associated with excess cardiovascular risk. In contrast to type 2 diabetes, however, age at the onset of type 1 diabetes and sex are major predictors of cardiovascular risk, while the role of low-density lipoprotein cholesterol (LDL-C) and lipid-lowering therapy is less clear. Since most data on the effects of lipid-lowering treatments are obtained from randomized clinical trials that included very predominantly patients with type 2 diabetes, it is almost impossible to specifically discern endpoints in type 1 diabetes. Inversely, most data specific for type 1 diabetes are obtained from real world findings. Consequently, the evidence on efficacy and safety of lipid-lowering therapies available from randomized clinical trials arises very predominantly from type 2 diabetes. Thus, this specific review summarizes the evidence of lipid-lowering drug classes in reducing cardiovascular risk in patients with type 1 diabetes.

Metrics

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Cardiac & Cardiovascular Systems
Pharmacology & Pharmacy
Logo image